DOCSLIB.ORG

Current Vaccines Volumes Per Child (Cm3)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Current Vaccines Volumes Per Child (Cm3) Current vaccines volumes per child (cm3) 450 400 350 Volumes,cm3 300 236.8 328.4 250 200 150 39 100 39 82.4 82.4 39 50 40.6 10.4 10.4 43.1 31.1 31.1 31.1 31.1 31.1 0 Tradi Vax TV+Penta_10d TV+Penta_1d TV+Penta 10d+PCV-10 TV+Penta_1d+PCV- TV+Penta_liq + PCV-10 10+Rota_liq + Rota_lyo Traditional Vax dtp/hepB/Hib combo PCV Rota_liq Rota_liq BCG vaccines • No. of manufacturers: 4 • Formulation: Lyophilized vaccine • Route of administration: ID injection • Schedule: 1 doses • Dosage: 0.05ml • Storage: +2° to +8°C, protect from light! • Type of VVM: VVM30 • MDVP: Keep cool reconstituted vial & Discard after six hours • Presentation: – 20-dose vials in boxes of 50: 1.3cm3/dose – 20-dose vials in boxes of 50: 1.6cm3/dose Tetanus Toxoid vaccines • No. of manufacturers: 6 • Formulation: Liquid vaccine • Route of administration: IM injection • Schedule: 2 doses • Dosage: 0.5ml • Storage: +2° to +8°C, Do not freeze! • Type of VVM: VVM30, 14, none • MDVP: Keep & use for subsequent sessions! • Presentations: – 1-dose Uniject in boxes of 100: 12.0cm3/dose – 1-dose ampoule in boxes of 50: 15.7cm3/dose – 2-dose vial in boxes of 50: 13.1cm3/dose – 10-dose vial in boxes of 10: 2.46cm3/dose – 10-dose vial in boxes of 10: 4.12cm3/dose – 10-dose vial in boxes of 30: 4.36cm3/dose – 10-dose vial in boxes of 50: 2.6cm3/dose – 20-dose vial in boxes of 10: 0.75cm3/dose – 20-dose vial in boxes of 10: 2.05cm3/dose – 20-dose vial in boxes of 20: 2.9cm3/dose – 20-dose vial in boxes of 25: 2.4cm3/dose – 20-dose vial in boxes of 30: 2.57cm3/dose Tetanus – Diphtheria Toxoid (Td) Vaccines • No. of manufacturers: 4 • Formulation: Liquid vaccine • Route of administration: IM injection • Schedule: 1 doses • Dosage: 0.5ml • Storage: +2° to +8°C, NEVER FREEZE! • VVM type: VVM 14, 30 • MDVP: Keep & use for subsequent sessions! • Presentations: – 1-dose ampoule in boxes of 50: 15.715cm3/dose (none) – 10-dose vial in boxes of 10: 2.23cm3/dose (vvm30) – 10-dose vial in boxes of 10: 2.611cm3/dose (vvm30) – 20-dose vial in boxes of 25: 2.433cm3/dose (vvm30) – 10-dose vial in boxes of 50: 2.46cm3/dose (none) – 10-dose vial in boxes of 10: 4.125cm3/dose (vvm14) temp suspension – 20-dose vial in boxes of 10: 2.05cm3/dose (vvm14) temp suspension Diphtheria-Tetanus (DT) Vaccines • No. of manufacturers: 4 • Formulation: Liquid vaccine • Route of administration: IM injection • Schedule: 3 doses • Dosage: 0.5ml • Storage: +2° to +8°C, NEVER FREEZE! • VVM type: VVM 14, 30 • MDVP: Keep & use for subsequent sessions! • Presentations: – 1-dose ampoule in boxes of 50: 15.715cm3/dose (none) – 10-dose vial in boxes of 10: 2.1Cm3/dose (vvm30) – 10-dose vial in boxes of 50: 2.611cm3/dose (vvm30) – 20-dose vial in boxes of 25: 2.433cm3/dose (vvm30) – 10-dose vial in boxes of 10: 2.46cm3/dose (none) – 10-dose vial in boxes of 10: 4.11cm3/dose (vvm14) – 20-dose vial in boxes of 10: 2.05cm3/dose (vvm14) temp suspension Measles vaccines • No. of manufacturers: 3 • Formulation: Lyophilized vaccine • Route of administration: SC injection • Schedule: 2 doses • Dosage: 0.5ml • Storage: +2° to +8°C, protect from light! • Type of VVM: VVM14 • MDVP: Keep cool reconstituted vial & Discard after six hours! • Presentation: – 1-dose vial in boxes of 50: 26.1cm3/dose – 2-dose vial in boxes of 50: 13.1cm3/dose – 5-dose vial in boxes of 50: 5.2cm3/dose – 10-dose vial in boxes of 50: 2.6cm3/dose – 20-dose vial in boxes of 50: 0.8cm3/dose Measles Rubella vaccines • No. of manufacturers: 2 • Formulation: Lyophilized vaccine • Route of administration: SC injection • Schedule: 2 doses • Dosage: 0.5ml • Storage: +2° to +8°C, protect from light! • Type of VVM: VVM14 • MDVP: Keep cool reconstituted vial & Discard after six hours! • Presentations: – 1-dose vial in boxes of 50: 26.1cm3/dose – 2-dose vial in boxes of 50: 13.1cm3/dose – 5-dose vial in boxes of 50: 5.2cm3/dose – 10-dose vial in boxes of 50: 2.6cm3/dose Measles, Mumps and Rubella vaccines • No. of manufacturers: 3 • Formulation: Lyophilized vaccine • Route of administration: SC injection • Schedule: 2 doses • Dosage: 0.5ml • Storage: +2° to +8°C, protect from light! • Type of VVM: VVM7 & 14 • MDVP: Keep cool reconstituted vial & Discard after six hours! • Presentations: – 1-dose vial in boxes of 10: 15.0cm3/dose – 1-dose vial in boxes of 50: 26.1cm3/dose – 2-dose vial in boxes of 50: 13.1cm3/dose – 5-dose vial in boxes of 50: 5.2cm3/dose – 10-dose vial in boxes of 50: 2.6cm3/dose Yellow fever vaccines • No. of manufacturers: 4 • Formulation: Lyophilized vaccine • Route of administration: SC injection • Schedule: 1 doses • Dosage: 0.5ml • Storage: +2° to +8°C, protect from direct light! • Type of VVM: VVM14 • MDVP: Keep cool reconstituted vial & Discard after six hours! • Presentations: – 2-dose vial in boxes of 10: 7.2cm3/dose – 5-dose vial in boxes of 10: 6.0cm3/dose – 5-dose vial in boxes of 50: 6.3cm3/dose – 10-dose vial in boxes of 50: 3.6cm3/dose – 10-dose vial in boxes of 10: 3.0cm3/dose – 20-dose vial in boxes of 10: 0.7cm3/dose – 50-dose vial in boxes of 50: 0.6cm3/dose Meningococcal A conjugate • No. of manufacturers: 1 • Formulation: Lyophilized vaccine • Route of administration: IM injection • Schedule: 1 doses • Dosage: 0.5ml • Storage: +2° to +8°C, protect from light! • Type of VVM: VVM30 • MDVP: Keep cool reconstituted vial & Discard after six hours! • Presentation: – 10-dose vials in boxes of 50: 2.6cm3/dose Hepatitis B vaccines • No. of manufacturers: 8 • Formulation: Liquid vaccine • Route of administration: IM injection • Schedule: 3 doses • Dosage: 0.5ml • Storage: +2° to +8°C, NEVER FREEZE! • Type of VVM: VVM30 • MDVP: Keep & use for subsequent sessions! • Presentations: – 1-dose Uniject in boxes of 100: 12.0cm3/dose – 1-dose vial in boxes of 35: 16.8cm3/dose – 2-dose vial in boxes of 36: 7.2cm3/dose – 6-dose vial in boxes of 30: 5.3cm3/dose – 10-dose vial in boxes of 30: 4.4cm3/dose – 20-dose vial in boxes of 30: 2.6cm3/dose DTP-HepB-Hib vaccines - liquid • No. of manufacturers: 3 • Formulation: Liquid vaccine • Route of administration: IM injection • Schedule: 3 doses • Dosage: 0.5ml • Storage: +2° to +8°C, NEVER FREEZE! • Type of VVM: VVM14 & 7 • MDVP: Keep & use for subsequent sessions! • Presentations: – 1-dose vial in boxes of 50: 13.1cm3/dose (vvm14) – 1-dose vial in boxes of 50: 10.3cm3/dose (vvm14) – 1-dose vial in boxes of 50: 26.1cm3/dose (vvm7) – 2-dose vial in boxes of 50: 13.1cm3/dose (vvm7) – 10-dose vial in boxes of 50: 2.6cm3/dose (vvm7) DTP-HepB+Hib vaccines – liquid+lyop. • No. of manufacturers: 3 • Formulation: Liquid+lyophilized vaccine • Route of administration: IM injection • Schedule: 3 doses • Dosage: 0.5ml • Storage: +2° to +8°C, NEVER FREEZE! • Type of VVM: VVM14 & 7 • MDVP: Keep cool reconstituted vial & Discard after six hours • Presentations: – 1-dose vial in boxes of 200: 39.2cm3/dose (vvm7) – 1-dose vial in boxes of 216: 58.7cm3/dose (vvm14) – 2-dose vial in boxes of 200: 19.6cm3/dose (vvm7) – 10-dose vial in boxes of 144: 7.5cm3/dose (vvm14) – 10-dose vial in boxes of 150: 5.1cm3/dose (vvm7) Haemophilus influenzae type b vaccines • No. of manufacturers: 3 • Formulation: Lyophilized vaccine • Route of administration: IM injection • Schedule: 3 doses • Dosage: 0.5ml • Storage: +2° to +8°C • Type of VVM: VVM14, 7 • Presentations: – 1-dose vial in boxes of 10: 39.2cm3/dose (vvm7) – 10-dose vial in boxes of 10: 7.5cm3/dose (vvm14) DTP-HepB vaccines • No. of manufacturers: 3 • Formulation: Liquid vaccine • Route of administration: IM injection • Schedule: 3 doses • Dosage: 0.5ml • Storage: +2° to +8°C, NEVER FREEZE! • Type of VVM: VVM14 & 7. • MDVP: Keep & use for subsequent sessions! • Presentations: – 1-dose vial in boxes of 50: 15.7cm3/dose (vvm7) – 1-dose vial in boxes of 50: 26.1cm3/dose (vvm7) – 2-dose vial in boxes of 50: xxcm3/dose (vvm14) – 5-dose vial in boxes of 10: 4.2cm3/dose (vvm14) – 10-dose vial in boxes of 10: 2.1cm3/dose (vvm14) – 10-dose vial in boxes of 50: 2.6cm3/dose (vvm7) – 20-dose vial in boxes of 25: 2.4cm3/dose (vvm7) DTP-Hib vaccines - liquid • No. of manufacturers: 2 • Formulation: Liquid vaccine • Route of administration: IM injection • Schedule: 3 doses • Dosage: 0.5ml • Storage: +2° to +8°C, NEVER FREEZE! • Type of VVM: VVM14, 7, • MDVP: Keep & use for subsequent sessions! • Presentations: – 1-dose vial in boxes of 50: 19.2cm3/dose (vvm7) – 10-dose vial in boxes of 10: 2.4cm3/dose (vvm14) DTP+Hib vaccines – liquid+lyop. • No. of manufacturers: 2 • Formulation: Lyophilized vaccine • Route of administration: IM injection • Schedule: 3 doses • Dosage: 0.5ml • Storage: +2° to +8°C, NEVER FREEZE! • Type of VVM: VVM7 & none • MDVP: Keep cool reconstituted vial & Discard after six hours • Presentations: – 1-dose vial in boxes of 10: 44.72cm3/dose (none) – 1-dose vial & ampoule in boxes of 1: 39.2cm3/dose (VVM-7) – 10-dose vial in boxes of 1: 12.4cm3/dose (none) Human Papilloma Virus vaccines HPV Gardasil: • Vaccine type: Quadravalent HPV (types 6, 11, 16 and 18) • Formulation: Liquid vaccine • Route of administration: IM injection • Schedule: 3 doses • Dosage: 0.5ml • Storage: +2° to +8°C, Do not freeze.
Load more

Recommended publications
  • New Brunswick COVID-19 Vaccine Clinic Guide for Immunizers
    New Brunswick COVID-19 Vaccine Clinic Guide for Immunizers Department of Health Public Health New Brunswick September 17, 2021 Public Health New Brunswick New Brunswick Department of Health PO Box 5100 Fredericton, New Brunswick, E3B 5G8 Canada This report is available online: www.gnb.ca/publichealth Ce document est aussi disponible en français sur le titre «Guide sur la vaccination contre la COVID-19 pour les Vaccinateurs du Nouveau-Brunswick ». TABLE OF CONTENTS NEW BRUNSWICK COVID-19 CLINIC GUIDE FOR IMMUNIZERS .......................................................... 1 1.0. PURPOSE ....................................................................................................................................... 1 2.0. VACCINE SOP ON TRANSPORTATION AND RECEIPT ............................................................. 1 Vaccines – storage and handling and maintaining cold chain to prevent temperature excursions (portable freezers and refrigeration) .......................................................... 2 3.0. SCHEDULES, DOSES AND ADMINISTRATION OF COVID-19 VACCINES ............................... 3 Carton Labelling of COVID-19 Vaccines ........................................................................ 4 4.0. REDUCING UNNECESSARY VACCINE WASTAGE .................................................................... 4 Context .............................................................................................................................. 4 Planning and prioritizing individual vaccination over wastage .................................
    [Show full text]
  • CARPHA COVID-19 Vaccine Update 015 April 19, 2021
    CARPHA UPDATE FOR Incident Manager / SITUATION REPORT COVID-19 Vaccines Update Supplement Week of: 19th April, 2021 I. Overview of Development and Regulatory Approvals: • 88 candidate vaccines are in clinical development: 16 in Phase 3 trials, and 4 in Phase 4 trials – see Figure in CARPHA COVID-19 Vaccine Regulatory Tracker (Phases tab). • 15 vaccines have received regulatory approvals in various countries, and 18 vaccines are at various stages of engagement with WHO for emergency use listing (EUL). • One additional AstraZeneca vaccine was approved by the WHO for Emergency Use Listing on 15th April, bringing the total number of listed COVID-19 vaccines by different manufacturers to 5: Pfizer-BioNTech’s vaccine: COMIRNATY®, AstraZeneca-SK Bio, AstraZeneca-SII (Covishield), Janssen-Cilag, AstraZeneca (EU node; Vaxzevria™) • 2 additional vaccines are expected to be approved by WHO in April, and 1 in May: Tables 1 and 3. • There is one additional vaccine being considered by WHO however it is at the stage of submitting expressions of interest: Bayer AG – Germany (CureVAC) • The WHO Global Advisory Committee on Vaccine Safety (GACVS) issued an interim statement indicating that based on current information, a causal relationship between the vaccine and the occurrence of rare blood clots with low platelets is considered plausible but is not confirmed. Specialised studies are needed to fully understand the potential relationship between vaccination and possible risk factors. The WHO maintains that the benefit-risk balance of the vaccine remains favorable. • CARPHA has shared its COVID-19 vaccine regulatory tracker with Member States for viewing as updates are made. • CARPHA-CRS has completed its review of the COVID-19 vaccine by Janssen-Cilag Pharmaceuticals (Johnson & Johnson), which will be finalized and shared with chief medical officers this week.
    [Show full text]
  • Supplemental Information and Guidance for Vaccination Providers Regarding Use of 9-Valent HPV Vaccine
    Supplemental information and guidance for vaccination providers regarding use of 9-valent HPV A 9-valent human papillomavirus (HPV) vaccine (9vHPV, Gardasil 9, Merck & Co.) was licensed for use in females and males in December 2014.1,2,3,4 The 9vHPV was the third HPV vaccine licensed in the United States by the Food and Drug Administration (FDA); the other vaccines are bivalent HPV vaccine (2vHPV, Cervarix, GlaxoSmithKline), licensed for use in females, and quadrivalent HPV vaccine (4vHPV, Gardasil, Merck & Co.), licensed for use in females and males.5 In February 2015, the Advisory Committee on Immunization Practices (ACIP) recommended 9vHPV as one of three HPV vaccines that can be used for routine vaccination of females and one of two HPV vaccines for routine vaccination of males.6 After the end of 2016, only 9vHPV will be distributed in the United States. In October 2016, ACIP updated HPV vaccination recommendations regarding dosing schedules.7 CDC now recommends two doses of HPV vaccine (0, 6–12 month schedule) for persons starting the vaccination series before the 15th birthday. Three doses of HPV vaccine (0, 1–2, 6 month schedule) continue to be recommended for persons starting the vaccination series on or after the 15th birthday and for persons with certain immunocompromising conditions. Guidance is needed for persons who started the series with 2vHPV or 4vHPV and may be completing the series with 9vHPV. The information below summarizes some of the recommendations included in ACIP Policy Notes and provides additional guidance.5-7 Information about the vaccines What are some of the similarities and differences between the three HPV vaccines? y Each of the three HPV vaccines is a noninfectious, virus-like particle (VLP) vaccine.
    [Show full text]
  • Adenoviral Vector COVID-19 Vaccines: Process and Cost Analysis
    processes Article Adenoviral Vector COVID-19 Vaccines: Process and Cost Analysis Rafael G. Ferreira 1,* , Neal F. Gordon 2, Rick Stock 2 and Demetri Petrides 3 1 Intelligen Brasil, Sao Paulo 01227-200, Brazil 2 BDO USA, LLP, Boston, MA 02110, USA; [email protected] (N.F.G.); [email protected] (R.S.) 3 Intelligen, Inc., Scotch Plains, NJ 07076, USA; [email protected] * Correspondence: [email protected] Abstract: The COVID-19 pandemic has motivated the rapid development of numerous vaccines that have proven effective against SARS-CoV-2. Several of these successful vaccines are based on the adenoviral vector platform. The mass manufacturing of these vaccines poses great challenges, especially in the context of a pandemic where extremely large quantities must be produced quickly at an affordable cost. In this work, two baseline processes for the production of a COVID-19 adenoviral vector vaccine, B1 and P1, were designed, simulated and economically evaluated with the aid of the software SuperPro Designer. B1 used a batch cell culture viral production step, with a viral titer of 5 × 1010 viral particles (VP)/mL in both stainless-steel and disposable equipment. P1 used a perfusion cell culture viral production step, with a viral titer of 1 × 1012 VP/mL in exclusively disposable equipment. Both processes were sized to produce 400 M/yr vaccine doses. P1 led to a smaller cost per dose than B1 ($0.15 vs. $0.23) and required a much smaller capital investment ($126 M vs. $299 M). The media and facility-dependent expenses were found to be the main contributors to the operating cost.
    [Show full text]
  • Overview of the Implementation of COVID-19 Vaccination Strategies and Deployment Plans in the EU/EEA
    [Type here] TECHNICAL REPORT Overview of the implementation of COVID-19 vaccination strategies and deployment plans in the EU/EEA 14 June 2021 Key messages This report provides an updated overview of the progress of national COVID-19 vaccination strategies in EU/EEA countries, including updates on: • overall vaccine uptake and uptake by target group; • current vaccination phases and priority groups, including adjustments made to priority groups during the rollout; • vaccination strategies and policies; • the use of vaccination certificates; • vaccine acceptance and hesitancy; and • challenges and good practice with the rollout. Vaccine COVID-19 rollout overview • As of 11 June 2021, a total of 333 678 903 COVID-19 vaccine doses have been distributed by manufacturers to European Union/European Economic Area (EU/EEA) countries, including over 39 million in the last week. Comirnaty (BNT162b2), developed by BioNTech/Pfizer, represents 67.3% of all doses distributed to EU/EEA countries via the European Commission’s Vaccine Strategy, followed by Vaxzevria (AZD1222), previously called COVID-19 Vaccine AstraZeneca (19.5%), COVID-19 Vaccine Moderna (9.6%), and COVID-19 Vaccine Janssen (3.3%). • A total of 284 124 689 vaccine doses have been administered in the EU/EEA, including over 25 million in the last week. Based on data available from 29 countries, 85% of the doses distributed in the EU/EEA since the beginning of the rollout have been administered. • Since the start of COVID-19 vaccine deployment in the EU/EEA in December 2020, the cumulative vaccine uptake in the adult population (aged 18 years and older) in the EU/EEA has progressed, reaching 51.2% for at least one vaccine dose (range: 14.9-67.7%) and 26.8% for the full vaccination course (range: 11.8-55.1%) (30 reporting countries).
    [Show full text]
  • An Overview of Nanocarrier-Based Adjuvants for Vaccine Delivery
    pharmaceutics Review An Overview of Nanocarrier-Based Adjuvants for Vaccine Delivery Kailash C. Petkar 1,*,†, Suyash M. Patil 2,†, Sandip S. Chavhan 3 , Kan Kaneko 4, Krutika K. Sawant 3, Nitesh K. Kunda 2,* and Imran Y. Saleem 4,* 1 Department of Scientific and Industrial Research, Ministry of Science & Technology, Government of India, New Delhi 110016, India 2 Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John’s University, Jamaica, NY 11439, USA; [email protected] 3 Department of Pharmaceutics, Faculty of Pharmacy, The Maharaja Sayajirao University of Baroda, Kalabhavan, Vadodara 390001, India; [email protected] (S.S.C.); [email protected] (K.K.S.) 4 School of Pharmacy and Biomolecular Sciences, Liverpool John Moores University, Liverpool L3 3AF, UK; [email protected] * Correspondence: [email protected] (K.C.P.); [email protected] (N.K.K.); [email protected] (I.Y.S.) † These authors contributed eqally to this work. Abstract: The development of vaccines is one of the most significant medical accomplishments which has helped to eradicate a large number of diseases. It has undergone an evolutionary process from live attenuated pathogen vaccine to killed whole organisms or inactivated toxins (toxoids), each of them having its own advantages and disadvantages. The crucial parameters in vaccination are the generation of memory response and protection against infection, while an important aspect is the effective delivery of antigen in an intelligent manner to evoke a robust immune response. In Citation: Petkar, K.C.; Patil, S.M.; Chavhan, S.S.; Kaneko, K.; Sawant, this regard, nanotechnology is greatly contributing to developing efficient vaccine adjuvants and K.K.; Kunda, N.K.; Saleem, I.Y.
    [Show full text]
  • Gsk Vaccines in 2010
    GSK VACCINES IN 2010 Thomas Breuer, MD, MSc Senior Vice President Head of Global Vaccines Development GSK Biologicals Vaccines business characteristics Few global players and high barriers to entry – Complex manufacturing – Large scale investment Long product life cycles – Complex intellectual property High probability of R&D success – 70% post-POC New technology/novel products Better pricing for newer vaccines – HPV vaccines (Cervarix, Gardasil) – Pneumococcal vaccines (Synflorix, Prevnar-13) Operating margin comparable to pharmaceutical products Heightened awareness New markets 2 Research & development timelines Identify Produce Pre-Clinical Proof of Registration/ Phase I Phase II Phase III File Antigens Antigens Testing Concept Post Marketing Research (inc. Immunology) Pre-Clinical Development (inc. Formulation Science) Clinical Development (inc. Post Marketing Surveillance) Transfer Process to Manufacturing Build Facility x x Up to $10-20M Up to $50-100M $500M - $1B x x x 1-10 yrs 2-3 yrs 2-4 yrs > 1 yr GSK vaccines business 2009 sales £3.7 billion (+30%) +19% CAGR excl. H1N1 Vaccines represent 13% since 2005 of total GSK sales Sale s (£m) 4000 3500 Recent approvals: 3000 US: Cervarix 2500 EU: Synflorix 2000 Pandemic: Pandemrix; Arepanrix 1500 1000 500 0 2005 2006 2007 2008 2009 Increased Emerging Market presence Growth rate is CER 5 GSK vaccines: fastest growing part of GSK in 2009 2009 Sales Share Growth (CER) Respiratory £ 6,977m 25% +5% Consumer £ 4,654m 16% +7% Anti-virals £ 4,150m 15% +12% Vaccines £ 3,706m 13% +30% CV & Urogenital
    [Show full text]
  • Responsive COVID-19 Vaccines for Recovery Project Under the Asia Pacific Vaccine Access Facility (Guaranteed by the Republic of Indonesia)
    Report and Recommendation of the President to the Board of Directors Project Number: 54425-001 March 2021 Proposed Loan PT Bio Farma (Persero) Responsive COVID-19 Vaccines for Recovery Project under the Asia Pacific Vaccine Access Facility (Guaranteed by the Republic of Indonesia) Distribution of this document is restricted until it has been approved by the Board of Directors. Following such approval, ADB will disclose the document to the public in accordance with ADB’s Access to Information Policy. CURRENCY EQUIVALENTS (as of 5 March 2021) Currency unit – rupiah (Rp) Rp1.00 = $0.0000697 $1.00 = Rp14,349 ABBREVIATIONS ADB – Asian Development Bank AEFI – adverse event following immunization APVAX – Asia Pacific Vaccine Access Facility Bio Farma – PT Bio Farma (Persero) COVID-19 – coronavirus disease Indofarma – PT Indofarma Tbk LIBOR – London interbank offered rate M&E – monitoring and evaluation MOH – Ministry of Health PAM – project administration manual RRC – rapid response component TA – technical assistance UNICEF – United Nations Children’s Fund VAP – Vaccination Allocation Plan VIRAT – Vaccination Introduction Readiness Assessment Tool WHO – World Health Organization NOTE In this report, “$” refers to United States dollars. Vice-President Ahmed M. Saeed, Operations 2 Director General Ramesh Subramaniam, Southeast Asia Department (SERD) Directors Ayako Inagaki, Human and Social Development Division (SEHS), SERD Winfried Wicklein, Country Director, Indonesia Resident Mission (IRM), SERD Said Zaidansyah, Deputy Country Director, IRM,
    [Show full text]
  • Optimal SARS-Cov-2 Vaccine Allocation Using Real-Time Seroprevalence Estimates in Rhode Island and Massachusetts
    medRxiv preprint doi: https://doi.org/10.1101/2021.01.12.21249694; this version posted January 15, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license . Optimal SARS-CoV-2 vaccine allocation using real-time seroprevalence estimates in Rhode Island and Massachusetts Thu Nguyen-Anh Tran1, Nathan Wikle2, Joseph Albert3, Haider Inam4, Emily Strong2, Karel Brinda5;6, Scott M Leighow4, Fuhan Yang1, Sajid Hossain7, Justin R Pritchard4, Philip Chan8, William P Hanage5, Ephraim M Hanks2, Maciej F Boni1 1 Center for Infectious Disease Dynamics, Department of Biology, Pennsylvania State University, University Park, PA 2 Center for Infectious Disease Dynamics, Department of Statistics, Pennsylvania State University, University Park, PA 3 Department of Physics, Pennsylvania State University, University Park, PA 4 Center for Infectious Disease Dynamics, Department of Bioengineering, Pennsylvania State University, University Park, PA 5 Center for Communicable Disease Dynamics, Department of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, MA 6 Department of Biomedical Informatics, Harvard Medical School, Boston, MA 7 Yale School of Medicine, Yale University, New Haven, CT 8 Department of Medicine, Brown University, Providence, RI Running Title: SARS-CoV-2 vaccination in RI and MA Keywords: SARS-CoV-2, vaccination, optimal vaccine allocation, mathematical modeling, real-time seroprevalence Date of this draft : January 12, 2021 ?Manuscript Correspondence: Maciej F. Boni Center for Infectious Disease Dynamics Department of Biology Pennsylvania State University University Park, PA tel +1 814 867 4651 email: [email protected] 1 NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.
    [Show full text]
  • Global Advisory Committee on Vaccine Safety (GACVS)
    Global Advisory Committee on Vaccine Safety (GACVS) Report on GACVS meeting June 2013 1 | GACVS June 2013 report Topics Discussed ! Pentavalent vaccine in 4 Asian Countries ! Zoster vaccine safety and varicella vaccine safety in immunocompromised populations ! Immunization during pregnancy ! Yellow fever vaccine safety during mass immunization campaigns in sub-Saharan Africa ! Safety profile: Japanese encephalitis vaccines ! Update: human papillomavirus vaccines ! Update: pandemic influenza vaccine (Pandemrix®) and narcolepsy 2 | GACVS June 2013 report Progressive pentavalent vaccine introduction in 4 Asian Countries ! Sri Lanka (Crucell, Jan 2008): – Within 3 months, 4 deaths and 24 suspected HHE: precautionary suspension of initial lot. – 1 death following immunization April 2009: vaccine suspended, DTwP and Hep B resumed. ! Bhutan (Panacea, Sep 2009) – 5 cases of encephalopathy and/or meningoencephalitis lead to suspended vaccination 23 Oct 2009. (Subsequently, 4 serious AEFI were identified and investigated). ! India (Serum Institute of India, Tamil Nadu and Kerala, Dec 2011; Goa, Pondicherry, Karnataka, Haryana, Jammu and Kashmir, Gujarat and Delhi from Q3 2012 – Q1 2013) – To date, 83 AEFI cases reported, some associated with mortality. ! Vietnam (Crucell, Jun 2010 - May 2013) – 43 serious AEFI investigated, including 27 with fatal outcome. – Following 9 deaths following vaccination reported Dec 2012 - March 2013: vaccine suspended. 3 | GACVS June 2013 report GACVS analysis of common features among countries experiencing significant vaccine safety concerns ! Vaccination programmes are well established and achieves high coverage ! Vaccine introduction was accompanied by thorough training of health-care staff on benefits and risks of vaccine ! Sri Lanka and Bhutan: discontinuation and resumption of pentavalent vaccine did not significantly modify pattern of serious AEFI with previously utilized vaccines ! Limitations in all 4 countries: – Incomplete clinical information complicated causality assessment.
    [Show full text]
  • Documentation of Vaccine Wastage in Two Different Geographic Contexts Under the Universal Immunization Program in India
    Documentation of vaccine wastage in two different geographic contexts under the universal immunization program in India Manoja Kumar Das ( [email protected] ) The INCLEN Trust International https://orcid.org/0000-0002-8559-5837 Mangla Sood Indira Gandhi Medical College Muralidhar Tambe BJ Medical College Thakur Dutt Sharma The INCLEN Trust International M A Parande BJ Medical College Jitendra B Surwade BJ Medical College N M Salunke BJ Medical College S S Patil BJ Medical College Bhagwan Pawar Ministry of Health and Family Welfare Rajesh Guleri Ministry of Health and Family Welfare Chitra Kaushal Ministry of Health and Family Welfare Monica Sindhu The INCLEN Trust International Research article Keywords: rotavirus vaccine, pneumococcal vaccine, routine immunization, outreach, vial size, vaccine wastage Posted Date: November 26th, 2019 DOI: https://doi.org/10.21203/rs.2.17806/v1 License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License Version of Record: A version of this preprint was published at BMC Public Health on April 25th, 2020. See the published version at https://doi.org/10.1186/s12889-020-08637-1. Page 1/10 Abstract Background Government of India is introducing new and relatively costly vaccines under immunization program. Monitoring of vaccine wastage is needed to guide the program implementation and forecasting. Under pilot introduction of rotavirus vaccine in two districts both 5- and 10-doses vials were used, which was considered as an opportunity for documenting the wastage. Methods A survey conducted in two districts (Kangra, Himachal Pradesh and Pune, Maharashtra) covered 49 vaccine stores, 34 sub-centres and 34 outreach sessions collected vaccine receipt, distribution and usage data for two complete years 2016 and 2017.
    [Show full text]
  • For the Use Only of a Registered Medical Practitioner Or a Hospital Or a Laboratory ENGERIX B Hepatitis B Vaccine
    For the use only of a Registered Medical Practitioner or a Hospital or a Laboratory ENGERIX® B Hepatitis B Vaccine (rDNA) IP (Genetically Engineered) 1. NAME OF THE MEDICINAL PRODUCT Hepatitis B Vaccine (rDNA) IP (Genetically Engineered) 2. QUALITATIVE AND QUANTITATIVE COMPOSITION ENGERIX B 20 mcg/1 ml (Adult) 1 dose (1 ml) contains : Equivalent to 20 mcg purified HBV surface antigen produced in Saccharomyces cerevisiae; Hydrated Aluminium Oxide IP equiv to 0.5 mg Aluminium ENGERIX B 10 mcg/0.5 ml (Paediatric) 1 dose (0.5 ml) contains: Equivalent to 10 mcg purified HBV surface antigen produced in Saccharomyces cerevisiae; Hydrated Aluminium Oxide IP equiv to 0.25 mg Aluminium For the full list of excipients, see section 6.1 List of excipients 3. PHARMACEUTICAL FORM Suspension for injection The suspension is turbid white. 4. CLINICAL PARTICULARS 4.1. Therapeutic indications ENGERIX B is indicated for active immunization against Hepatitis B Virus infection (HBV) caused by all known subtypes in subjects of all ages considered at risk of exposure to HBV. It can be expected that hepatitis D will also be prevented by immunization with ENGERIX B as hepatitis D (caused by the delta agent) does not occur in the absence of hepatitis B infection. Immunization against hepatitis B is expected in the long term to reduce not only the incidence of this disease but also its chronic complication such as chronic active hepatitis B and hepatitis B associated cirrhosis. In areas of low prevalence of hepatitis B, immunization is particularly recommended for those belonging to groups identified at increased risk of infection (see below), however, universal immunization of all infants and adolescents will contribute to the control of hepatitis B on a population basis.
    [Show full text]